Revolution Medicines' new drug, Daraxonrasib, doubled overall survival to 13.2 months in a Phase III pancreatic cancer trial—a remarkable development against a cancer that has resisted decades of progress.
Daraxonrasib targets RAS mutations, which appear in 30% of all cancers and over 90% of pancreatic cases. RAS has long been considered one of the hardest targets in oncology to develop drugs against.
We believe the breakthrough is likely a catalyst for the wider field, drawing more development and Big Pharma interest to RAS-targeted therapies.
Pancreatic cancer is among the deadliest cancers with just a 13% five-year survival rate.1 It is hard to detect, progresses aggressively, and is often resistant to treatments, including chemotherapy.
On April 13, that began to change.
RAS is a family of three oncogenes (KRAS, NRAS, and HRAS) that cause cancer when mutated. RAS mutations appear in 30% of all cancers and are a key pathway for disease progression. For some major cancers RAS drivers are more important than others. KRAS drives more than 90% of pancreatic cancers. For decades, RAS was seen as difficult to target with a drug due to protein structure and lack of obvious binding sites.
Revolution Medicines reported results for Daraxonrasib. Daraxonrasib is a multi-selective RAS(ON) inhibitor, designed to block the active signaling form of RAS, across multiple mutation types. The drug shuts down the broader RAS signaling network, which is central to tumor growth.
The data was monumental. In a Phase III trial of patients who had failed a first-line treatment, Daraxonrasib doubled overall survival to 13.2 months. That exceeds typical first-line outcomes, where treatment effects are usually strongest.
If the drug moves into first-line treatment, it could replace side-effect-heavy chemotherapy with a more precise alternative.
This may be the beginning of biotech finally meeting pancreatic cancer head on. It reminds us of what Opdivo and Keytruda, the PD-1 targeting agents, did to melanoma or what other treatments did for multiple myeloma and leukemia: dramatically improving survival in previously fatal conditions. Given how common RAS mutations are, the opportunity extends across multiple cancers, especially in combination treatments. It heralds a new generation of cancer blockbusters, just as PD-1 checkpoint inhibitors go generic.
Many companies are pursuing RAS targets, and the space is heating up. Big Pharma, keen to replace expiring patents with innovation, is likely to follow. There was speculation that Merck was looking to buy Revolution Medicines earlier this year.2
Companies Working on RAS Targets
| Revolution Medicines | |
| Verastem | |
| Immuneering | |
| Erasca | |
| Adlai Nortye | |
| Roche | |
| Eli Lilly | |
| Innovent Biologics | |
| Amgen | |
| Bristol Myers Squibb | |
| Jacobio Pharmaceuticals | |
| Astellas Pharma |
Source: Tema Analysis, as of Apr 2026
RAS mutations represent one of the most important unaddressed targets in oncology. The clinical readout from Revolution Medicines suggests that, for the first time, a drug can meaningfully disrupt RAS-driven tumor growth across multiple mutation types. If Daraxonrasib moves into first-line treatment and combination regimens, the addressable patient population expands dramatically, and the commercial opportunity follows. The parallels to PD-1 checkpoint inhibitors in their early phase are instructive: a single validated mechanism attracted a wave of development capital, strategic acquisitions, and ultimately transformed standard of care across multiple cancer types. RAS inhibition may follow the same arc.
For investors looking to invest behind innovation, the Tema Oncology ETF (CANC) invests in a collection of companies delivering breakthroughs and features Revolution Medicines as its top holding.*
*Portfolio holdings are subject to change. For current holdings, visit the CANC fund page.